1. Scrip

Civica Takes On The Challenge Of Insulin Affordability

It Will Set Its Own Price Caps

 
• By Jessica Merrill

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

insulin pen
Civica hopes to tackle the high cost of insulin • Source: Alamy

As insulin pricing remains a focus in the US political debate around drug pricing, the non-profit generic pharmaceutical company Civica, Inc. announced a plan to develop and distribute three types of insulin with the aim of addressing affordability.

The organization said on 3 March that it plans to develop and produce biosimilar versions of three insulins – Sanofi's Lantus (insulin glargine), Eli Lilly and Company's Humalog (insulin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.